L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Based on its proprietary expression system, Eukarÿs develops a radically novel, safe and efficient synthetic gene therapy for liver diseases and cancer, currently at preclinical stage, as well as high performance bioproduction systems for biologics
Evry, Île-de-France, France
Send a message
Eukarÿs is nominated among 9 other European companies at the EIT Health Summit 2019 at the Investor Network Start-Ups. The 2019 EIT Health Summit will be held at the Palais Brongniart in Paris on 2 and 3 December 2019.
Eukarÿs today announces the excellent preclinical performance of its first synthetic gene therapy treatment. This treatment called EUK-LPR ("Eukarÿs Liver ProRegeneration") is designed to reduce mortality and morbidity following partial hepatic resection by inducing liver regeneration prior to this surgical procedure. For specifically tumor indications of hepatectomy, including liver metastases of colorectal cancer, EUK-LPR will be associated with another synthetic gene therapy treatment whose development will be announced in 2020.
The tests performed in rats confirmed the excellent performance of EUK-LPR, since an 18% increase in hepatic mass is observed in animals in just 4 days after injection of an advanced EUK-LPR prototype. These results follow an extensive phase of preclinical optimization of the artificial gene whose expression is made possible by synthetic gene therapy. No signs of toxicity or poor tolerance have been observed in animals.
Philippe Jais, President & Scientific Director of Eukarÿs said: "We are delighted by these new results, which reinforce the considerable work undertaken over two years ago. EUK-LPR is designed to reduce the mortality of major hepatectomy, a major surgical procedure performed in more than 50,000 patients each year. We expect to start the regulatory phases at the end of 2020-early 2021 and the clinical phases by 2023. »
Eukarÿs is proud to announce winning the Galien MedStartUp Award 2019 in the category of Best Collaboration with the Pharmaceutical or Biotechnology Industry. This highly prestigious award, presented Thursday, October 24 in New York at the Alexandria Life Sciences Center, recognizes the best scientific innovations for human health. Eukarÿs partnership with the University of Alberta's Molecular Virology and Oncology Laboratory, led by Dr. Maya Shmulevitz, has been recognized. This collaboration has led to the development of the C3P3 system for viral bioproduction applications, particularly reoviruses used oncolytically. This award was presented by a committee chaired by Bernard Poussot (President of Roche Holding) and comprising leaders of the largest companies in the pharmaceutical industry (Sanofi, GSK, Pfizer, Johnson & Johnson, UCB) and venture capital (EvercorePartners).
Eukarÿs is a biotechnology company from the biocluster of the Evry Genopole (France) which has developed the first and only eukaryotic artificial expression system called C3P3. This system allows high-yield production of mature messenger RNAs in host cells and thus proteins of interest.
Thanks to the C3P3 system, Eukarÿs has developed a radically innovative therapeutic approach called synthetic gene therapy based on the administration of synthetic DNA. Gene therapy, whose efficacy and safety of use is now demonstrated in preclinical studies, has been designed to provide practical solutions to almost all of the challenges faced by gene therapy.
Start in 20/03/2010
In vitro POC of our core technology - the C3P3 system - is obtained and the patent is filled
Eukarÿs is founded as a SAS
Eukarÿs wins i-LAB, the award from the French Ministry for Research (€450,000)
C3P3-G1 patent is granted in Europe
C3P3-G1 patent is granted in the USA
to be continued ...